By Fineline Cube GenFleet Therapeutics (HKG: 2595) announced that “Kylin‑Flight 01,” the registrational Phase 3 clinical trial of GFH375 as monotherapy for non‑small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet’s clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.
Trial Overview
| Item | Detail |
|---|---|
| Study Name | Kylin‑Flight 01 |
| Phase | Registrational Phase 3 |
| Treatment | GFH375 monotherapy |
| Indication | KRAS G12D‑mutant non‑small cell lung cancer (NSCLC) |
| Region | China |
| Status | Initiated; first patient enrolled |
Drug Profile & Mechanism of Action
- Molecule: GFH375, an orally administered KRAS G12D inhibitor
- Mechanism: Non‑covalently binds the KRAS G12D protein, inhibiting its interaction with downstream effector proteins; this disrupts persistent activation of downstream signaling pathways driven by KRAS G12D, ultimately achieving potent inhibition of tumor cell proliferation.
- Differentiation: KRAS G12D is one of the most common yet historically difficult‑to‑target KRAS mutations, making oral, non‑covalent inhibition a notable mechanistic approach in precision oncology.
Clinical Pipeline & Regulatory Designations
| Program | Indication | Status |
|---|---|---|
| Kylin‑Flight 01 | KRAS G12D‑mutant NSCLC | Phase 3 initiated (first patient enrolled) |
| Kylin‑Wings 01 | Pancreatic cancer | Registrational Phase 3 (already underway) |
- Breakthrough Therapy Designation (BTD): GFH375 monotherapy has received BTD for both KRAS G12D‑mutant NSCLC and pancreatic cancer, underscoring the potential of the asset in high‑unmet‑need indications.
Partnership & Commercial Rights
| Region | Rights Holder | Development Code |
|---|---|---|
| Outside China | Verastem | VS‑7375 |
| Within China | GenFleet Therapeutics | GFH375 |
GenFleet has granted Verastem the rights to develop and commercialize GFH375 outside of China, while GenFleet retains all rights within China — a structure that splits global commercial exposure between the two companies.
Market Impact & Outlook
- KRAS G12D Race: The initiation of a second registrational Phase 3 study positions GFH375 among the most clinically advanced KRAS G12D inhibitors, an area of intense competition and investor interest following early KRAS G12C successes.
- Regulatory Momentum: Dual Breakthrough Therapy Designations in NSCLC and pancreatic cancer may support expedited review pathways in both indications.
- Pipeline Breadth: Parallel Phase 3 programs in lung and pancreatic cancer broaden the asset’s commercial optionality across two of the most lethal solid tumors harboring KRAS G12D mutations.
- Global Strategy: The Verastem partnership provides a development and commercialization pathway outside China, while GenFleet retains full upside in its home market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory outcomes, and commercialization of GFH375 (VS‑7375). Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.-Fineline Info & Tech